John V. Heymach

67.1k citations

635 papers · 25.2k indexed · 14 hit papers · h-index 79

Oncology top 0.05%
- Cancer Immunotherapy and Biomarkers 130
- Lung Cancer Research Studies 98
- Colorectal Cancer Treatments and Studies 66
Cancer Research top 0.1%
- Cancer Genomics and Diagnostics 108
Pulmonary and Respiratory Medicine top 0.05%
- Lung Cancer Treatments and Mutations 282
- Lung Cancer Diagnosis and Treatment 85
Molecular Biology top 0.2%
- RNA modifications and cancer 52
- Angiogenesis and VEGF in Cancer 42
Immunology top 0.5%

Co-authors: Roy S. Herbst Scott M. Lippman Ferdinandos Skoulidis Lauren A. Byers Jing Wang Tina Cascone Ignacio I. Wistuba Monique B. Nilsson
Cited by: Oncology Cancer Research Pulmonary and Respiratory Medicine
Journals: New England Journal of Medicine (2 papers)Proceedings of the National Academy of Sciences (1 paper)Journal of Biological Chemistry (4 papers)
Partner nations: United States China Japan

In The Last Decade

John V. Heymach

603 papers receiving 24.9k citations

Hit Papers

14 papers align trajectories log scale

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

2024 Nature Reviews Disease Primers
2023 Heliyon
2023 npj Precision Oncology
2022 Clinical Cancer Research
2020 Journal of Thoracic Oncology
2020 The Lancet Respiratory Medicine
2019 Cancer Discovery
2019 Nature reviews. Cancer
2019 Nature reviews. Cancer
2018 Journal of Clinical Oncology
2016 Clinical Cancer Research
2014 Cancer Immunology Research
2008 New England Journal of Medicine
2007 Cancer Research

Peers

Countries citing papers authored by John V. Heymach

Since Specialization

Citations

This map shows the geographic impact of John V. Heymach's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John V. Heymach with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John V. Heymach more than expected).

Fields of papers citing papers by John V. Heymach

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John V. Heymach. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John V. Heymach. The network helps show where John V. Heymach may publish in the future.

Co-authorship network

The 25 scholars most cited alongside John V. Heymach, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with John V. Heymach Line = papers co-authored together John V. Heymach links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Abstract CT005: AEGEAN: A phase 3 trial of neoadjuvant durvalumab + chemotherapy followed by adjuvant durvalumab in patients with resectable NSCLC Cancer Research ·John V. Heymach,David H. Harpole,Tetsuya Mitsudomi,Janis M. Taube,Gabriella Gálffy,Maximilian J. Hochmair,Thomas Winder,Р. А. Зуков,Gabriel Garbaos,Shugeng Gao,Hiroaki Kuroda,Jian You,Kang‐Yun Lee,Lorenzo Antonuzzo,Mike Aperghis,Gary J. Doherty,Helen Mann,Tamer M. Fouad,Martin Reck	2023	55
2	AXL Inhibition Induces DNA Damage and Replication Stress in Non–Small Cell Lung Cancer Cells and Promotes Sensitivity to ATR Inhibitors Molecular Cancer Research ·Kavya Ramkumar,C. Allison Stewart,Kasey R. Cargill,Carminia Maria Della Corte,Qi Wang,Li Shen,Lixia Diao,Robert J. Cardnell,David H. Peng,B. Leticia Rodriguez,You-Hong Fan,John V. Heymach,Jing Wang,Carl M. Gay,Don L. Gibbons,Lauren A. Byers	2020	38
3	STK11 /LKB1 Mutations in NSCLC Are Associated with KEAP1/NRF2-Dependent Radiotherapy Resistance Targetable by Glutaminase Inhibition Clinical Cancer Research ·Piyada Sitthideatphaiboon,Ana Galan Cobo,Marcelo V. Negrão,Xiao Qu,Alissa Poteete,Fahao Zhang,Diane D. Liu,Whitney E. Lewis,Haley N. Kemp,Jeff Lewis,Waree Rinsurongkawong,Uma Giri,J. Jack Lee,Jianjun Zhang,Jack A. Roth,Stephen G. Swisher,John V. Heymach	2020	57
4	Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancerbreakdown → Cancer Discovery ·Triparna Sen,B. Leticia Rodriguez,Limo Chen,Carminia Maria Della Corte,Naoto Morikawa,Junya Fujimoto,Sandra Cristea,Thuyen Nguyen,Lixia Diao,Lerong Li,You-Hong Fan,Yongbin Yang,Jing Wang,Bonnie S. Glisson,Ignacio I. Wistuba,Julien Sage,John V. Heymach,Don L. Gibbons,Lauren A. Byers	2019	616
5	Inhibition of Thioredoxin/Thioredoxin Reductase Induces Synthetic Lethality in Lung Cancers with Compromised Glutathione Homeostasis Cancer Research ·Xiang Yan,Xiaoshan Zhang,Li Wang,Ran Zhang,Xingxiang Pu,Shuhong Wu,Lei Li,Pan Tong,Jing Wang,Qing H. Meng,V. Behrana Jensen,Luc Girard,John D. Minna,Jack A. Roth,Stephen G. Swisher,John V. Heymach,Bingliang Fang	2018	62
6	Differential Sensitivity Analysis for Resistant Malignancies (DISARM) Identifies Common Candidate Therapies across Platinum-Resistant Cancers Clinical Cancer Research ·Carl M. Gay,Pan Tong,Robert J. Cardnell,Triparna Sen,Xiao Hua Su,Jun Ma,Rasha O. Bara,Faye M. Johnson,Chris Wakefield,John V. Heymach,Jing Wang,Lauren A. Byers	2018	12
7	CDKN2A/p16 Deletion in Head and Neck Cancer Cells Is Associated with CDK2 Activation, Replication Stress, and Vulnerability to CHK1 Inhibition Cancer Research ·Mayur A. Gadhikar,Jiexin Zhang,Li Shen,Xiayu Rao,Jing Wang,Mei Zhao,Nene N. Kalu,Faye M. Johnson,Lauren A. Byers,John V. Heymach,Walter N. Hittelman,Durga Udayakumar,Raj K. Pandita,Tej K. Pandita,Curtis R. Pickering,Abena B. Redwood,Helen Piwnica‐Worms,Katharina Schlacher,Mitchell J. Frederick,Jeffrey N. Myers	2017	34
8	Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells Clinical Cancer Research ·Chad Tang,James W. Welsh,Patricia M. de Groot,Erminia Massarelli,Joe Y. Chang,Kenneth R. Hess,Sreyashi Basu,Michael A. Curran,Maria E. Cabanillas,Vivek Subbiah,Siqing Fu,Apostolia M. Tsimberidou,Daniel D. Karp,Daniel R. Gomez,Adi Diab,Ritsuko Komaki,John V. Heymach,Padmanee Sharma,Aung Naing,David S. Hong	2016	251
9	Image Analysis–based Assessment of PD-L1 and Tumor-Associated Immune Cells Density Supports Distinct Intratumoral Microenvironment Groups in Non–small Cell Lung Carcinoma Patients Clinical Cancer Research ·Edwin R. Parra,Carmen Behrens,Jaime Rodriguez‐Canales,Heather Lin,Barbara Mino,Jorge Blando,Jianjun Zhang,Don L. Gibbons,John V. Heymach,Boris Sepesi,Stephen G. Swisher,Annikka Weissferdt,Neda Kalhor,Julie Izzo,Humam Kadara,César A. Moran,J. Jack Lee,Ignacio I. Wistuba	2016	103
10	AXL Inhibition Suppresses the DNA Damage Response and Sensitizes Cells to PARP Inhibition in Multiple Cancers Molecular Cancer Research ·Kavitha Balaji,Smruthi Vijayaraghavan,Lixia Diao,Pan Tong,You-Hong Fan,Jason P.W. Carey,Tuyen Bui,Steve Warner,John V. Heymach,Kelly K. Hunt,Jing Wang,Lauren A. Byers,Khandan Keyomarsi	2016	70
11	Phase II Trial of Erlotinib Plus Concurrent Whole-Brain Radiation Therapy for Patients With Brain Metastases From Non–Small-Cell Lung Cancer Journal of Clinical Oncology ·James W. Welsh,Ritsuko Komaki,Arya Amini,Mark F. Munsell,Wyatt Unger,Pamela K. Allen,Joe Y. Chang,Jeffrey S. Wefel,Susan L. McGovern,Linda L. Garland,Su S. Chen,J.A. Holt,Zhongxing Liao,Paul D. Brown,Erik P. Sulman,John V. Heymach,Edward S. Kim,Baldassarre Stea	2013	314
12	Proteomic Markers of DNA Repair and PI3K Pathway Activation Predict Response to the PARP Inhibitor BMN 673 in Small Cell Lung Cancer Clinical Cancer Research ·Robert J. Cardnell,Ying Feng,Lixia Diao,You-Hong Fan,Fatemah Masrorpour,Jing Wang,Yuqiao Shen,Gordon B. Mills,John D. Minna,John V. Heymach,Lauren A. Byers	2013	131
13	The SUMO E3-ligase PIAS1 Regulates the Tumor Suppressor PML and Its Oncogenic Counterpart PML-RARA Cancer Research ·Andrea Rabellino,Brandon Carter,Georgia Konstantinidou,Shwu-Yuan Wu,Alessandro Rimessi,Lauren A. Byers,John V. Heymach,Luc Girard,Cheng-Ming Chiang,Julie Teruya‐Feldstein,Pier Paolo Scaglioni	2012	94
14	Vandetanib Restores Head and Neck Squamous Cell Carcinoma Cells' Sensitivity to Cisplatin and Radiation In Vivo and In Vitro Clinical Cancer Research ·Daisuke Sano,Fumihiko Matsumoto,David R. Valdecanas,Mei Zhao,David Molkentine,Yoko Takahashi,Ehab Y. Hanna,Vali Papadimitrakopoulou,John V. Heymach,Luka Milas,Jeffrey N. Myers	2011	59
15	Robust Gene Expression Signature from Formalin-Fixed Paraffin-Embedded Samples Predicts Prognosis of Non–Small-Cell Lung Cancer Patients Clinical Cancer Research ·Yang Xie,Guanghua Xiao,Kevin R. Coombes,Carmen Behrens,Luisa M. Solis,Gabriela Raso,Luc Girard,Heidi S. Erickson,Jack A. Roth,John V. Heymach,César A. Moran,K. D. Danenberg,John D. Minna,Ignacio I. Wistuba	2011	130
16	Increased VEGFR-2 Gene Copy Is Associated with Chemoresistance and Shorter Survival in Patients with Non–Small-Cell Lung Carcinoma Who Receive Adjuvant Chemotherapy Cancer Research ·Fei Yang,Ximing Tang,Erick Riquelme,Carmen Behrens,Monique B. Nilsson,Uma Giri,Marileila Varella‐Garcia,Lauren A. Byers,Heather Lin,Jing Wang,Maria Gabriela Raso,Luc Girard,Kevin R. Coombes,J. Jack Lee,Roy S. Herbst,John D. Minna,John V. Heymach,Ignacio I. Wistuba	2011	51
17	DNA Repair Biomarker Profiling of Head and Neck Cancer: Ku80 Expression Predicts Locoregional Failure and Death following Radiotherapy Clinical Cancer Research ·Benjamin J. Moeller,John S. Yordy,Michelle D. Williams,Uma Giri,Uma Raju,David Molkentine,Lauren A. Byers,John V. Heymach,Michael D. Story,J. Jack Lee,Erich M. Sturgis,Randal S. Weber,Adam S. Garden,K. Kian Ang,David A. Schwartz	2011	75
18	Steroid Receptor Coactivator-3 Expression in Lung Cancer and Its Role in the Regulation of Cancer Cell Survival and Proliferation Cancer Research ·Di Cai,David S. Shames,Maria Gabriela Raso,Yang Xie,Young Ho Kim,Jonathan R. Pollack,Luc Girard,James P. Sullivan,Boning Gao,Michael Peyton,Meera Nanjundan,Lauren A. Byers,John V. Heymach,Gordon B. Mills,Adi F. Gazdar,Ignacio I. Wistuba,Thomas Kodadek,John D. Minna	2010	48
19	Baseline Vascular Endothelial Growth Factor Concentration as a Potential Predictive Marker of Benefit from Vandetanib in Non–Small Cell Lung Cancer Clinical Cancer Research ·Emer O. Hanrahan,Anderson J. Ryan,Helen Mann,S. Kennedy,Peter Langmuir,Ronald B. Natale,Roy S. Herbst,Bruce E. Johnson,John V. Heymach	2009	69
20	Metronomic Chemotherapy Enhances the Efficacy of Antivascular Therapy in Ovarian Cancer Cancer Research ·Aparna A. Kamat,Tae Jin Kim,Charles N. Landen,Chunhua Lu,Liz Y. Han,Yvonne G. Lin,William M. Merritt,Premal H. Thaker,David M. Gershenson,Farideh Z. Bischoff,John V. Heymach,Robert B. Jaffe,Robert L. Coleman,Anil K. Sood	2007	113

About John V. Heymach

John V. Heymach is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine, having authored 635 papers that have together received 25.2k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (282 papers), Cancer Immunotherapy and Biomarkers (130 papers), Cancer Genomics and Diagnostics (108 papers), Lung Cancer Research Studies (98 papers), Lung Cancer Diagnosis and Treatment (85 papers), Colorectal Cancer Treatments and Studies (66 papers), RNA modifications and cancer (52 papers) and Angiogenesis and VEGF in Cancer (42 papers). The work is most often cited by research in Oncology (13.6k citations), Cancer Research (5.4k citations) and Pulmonary and Respiratory Medicine (10.2k citations). John V. Heymach has collaborated with scholars based in United States, China and Japan. Frequent co-authors include Roy S. Herbst, Scott M. Lippman, Ferdinandos Skoulidis, Lauren A. Byers, Jing Wang, Tina Cascone, Ignacio I. Wistuba, Monique B. Nilsson, Lixia Diao and Xiuning Le. Their work appears in journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact